Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (632)	2/23/2007 8:49:53 PM
From: Jibacoa	Read Replies (1) \| Respond to of 802

Gendicine's press on h/n tells me that the Fuerstine et. al. negativity is at least partially based on a daily dose of bull.. Yes, people are going to China to receive treatments with Gendicine, which is similar if not identical to ADVEXIN.(But I still like INGN 241 even better.<g>) In clinical trials, Gendicine has been used to successfully treat cancers of the digestive tract (esophageal, gastric,intestine, liver, pancreas, gallbladder,rectum), lung cancer, sarcoma, thyroid-gland cancer, breast cancer, cervical cancer,and ovarian cancer. Although Gendicine has not been formally approved by SFDA for indications other than HNSCC, terminal patients with no other avenue of treatment have been allowed, on a case-by-case basis, to receive Gendicine with permission from the SFDA, along with a request from the patient, the patient’s family, and the agreement of the patient’s doctor. They also insist that the patient, family, and the doctor-in-charge carefully read and endorse the informed consent forms. During more than three years of follow-up for the twelve patients with mid to-late-stage laryngeal cancer who received Gendicine therapy in phase 1 clinical trials,no patient has relapsed. By contrast,among patients who received only surgery, the three-year relapse rate is approximately 30%. And patients do not have to stay on the drug for the rest of their lives. A patient receives one injection per week for four to eight weeks consecutively as a treatment cycle. Bernard